Drugs / Sacubitril/Valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03508739 | Jun 2018 → Jun 2026 | hypertensive disorder, prediabetes syndrome, type 2 diabetes mellitus | University of Pennsylvania | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/Valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03508739 ↗ |
| Action | Inhibit | “neprilysin inhibition with sacubitril/valsartan” NCT03508739 ↗ |
| Route | Oral | “sacubitril/valsartan 200mg po” NCT03508739 ↗ |